US-based medical device company SI-BONE has reported positive results of the Investigation of Sacroiliac Fusion Treatment (INSITE) study of its iFuse Implant System compared with non-surgical management (NSM) for Sacroiliac Joint Dysfunction.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The iFuse Implant System is designed as a minimally invasive surgical option that uses titanium implants with a porous surface acting as an interference surface, to help decrease implant motion, and facilitate biological fixation to support long term fusion.

The device is intended to be used for sacroiliac fusion for conditions namely sacroiliac joint dysfunction, which is directly attributed to sacroiliac joint disruption and degenerative sacroiliitis.

The INSITE study was designed as a prospective, multicentre, randomised controlled trial which involved 148 patients, out of who, 102 patients were treated with iFuse device while the rest were treated with the NSM.

Results suggested that the iFuse group experienced reduction in their joint pain with a decrease in disability determined on the basis of Oswestry Disability Index (ODI).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"This positive publication validates the consistency of the earlier publications on iFuse and will hopefully encourage health plans across the US to establish coverage for this effective procedure."

Rush University Medical Center in Chicago MD Frank Phillips said: "These two-year results from the INSITE study illustrate the durability of SI joint fusion with iFuse and further validate previously reported 6- and 12-month results that showed rapid improvement in pain, function and quality of life in this highly debilitated patient population.

"This positive publication validates the consistency of the earlier publications on iFuse and will hopefully encourage health plans across the US to establish coverage for this effective procedure."

Clinical studies that were conducted earlier have also demonstrated the efficacy of the iFuse Implant System in improving pain, patient function, and quality of life.


Image: Graphical illustration of study results of iFuse Implant System. Photo: courtesy of PRNewsFoto/SI-BONE, Inc.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact